Latest Pharma Insights
Insilico’s Bold Move To Take AI-Discovered Asset Into Phase III
Unable to find a partner to share the risk on its novel idiopathic pulmonary fibrosis asset, Insilico is moving into late-stage testing on its own.
Scrip - July 8, 2026
Unable to find a partner to share the risk on its novel idiopathic pulmonary fibrosis asset, Insilico is moving into late-stage testing on its own.
Scrip - July 8, 2026
Deals Shaping The Industry, June 2026
An interactive look at pharma, medtech and diagnostics deals made during June 2026. Data courtesy of Biomedtracker.
In Vivo - July 8, 2026
An interactive look at pharma, medtech and diagnostics deals made during June 2026. Data courtesy of Biomedtracker.
In Vivo - July 8, 2026
ResMed Sells MatrixCare Software Business For $490m In Portfolio Overhaul
The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy.
Medtech Insight - July 8, 2026
The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy.
Medtech Insight - July 8, 2026
Vera Edges Vertex In IgAN Race As FDA Approves Trutakna
Trutakna becomes the first BAFF/APRIL inhibitor approved for IgAN, a new approach in a market already crowded with several therapies.
Scrip - July 8, 2026
Trutakna becomes the first BAFF/APRIL inhibitor approved for IgAN, a new approach in a market already crowded with several therapies.
Scrip - July 8, 2026
Amneal Gets Selected For US FDA’s Domestic Manufacturing Pilot
Amneal's new Brookhaven sterile plant joins six other facilities in the FDA's PreCheck pilot, which fast-tracks regulatory engagement for domestic manufacturers.
Generics Bulletin - July 8, 2026
Amneal's new Brookhaven sterile plant joins six other facilities in the FDA's PreCheck pilot, which fast-tracks regulatory engagement for domestic manufacturers.
Generics Bulletin - July 8, 2026
‘Crises And Challenges’ – How An Embattled European Off-Patent Industry Is Fighting Global Pressures
With Europe’s off-patent industry struggling to deal with pressures including the Urban Waste Water Treatment Directive, the impact of the US MFN policy and competition from China, Medicines for Europe’s leaders talk about how the generics and biosimilars sector is pushing back.
Generics Bulletin - July 8, 2026
With Europe’s off-patent industry struggling to deal with pressures including the Urban Waste Water Treatment Directive, the impact of the US MFN policy and competition from China, Medicines for Europe’s leaders talk about how the generics and biosimilars sector is pushing back.
Generics Bulletin - July 8, 2026
Split Federal Circuit Keeps Hetero’s Nuedexta Generic Sidelined
Otsuka has fended off Hetero Labs’ US generic version of its Nuedexta at the Federal Circuit, which upheld a preliminary injunction blocking the generic – but only until the underlying patent expires in August, and on condition that Otsuka now posts a bond.
Generics Bulletin - July 8, 2026
Otsuka has fended off Hetero Labs’ US generic version of its Nuedexta at the Federal Circuit, which upheld a preliminary injunction blocking the generic – but only until the underlying patent expires in August, and on condition that Otsuka now posts a bond.
Generics Bulletin - July 8, 2026
Physicians Reviewing ChatGPT Responses To Improve Healthcare Answers
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
HBW Insight - July 8, 2026
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
HBW Insight - July 8, 2026
The Race To Commercialize Functional Precision Medicine And The Policy Battle Shaping It
Early data from ex vivo drug sensitivity platforms suggest functional precision medicine could transform cancer treatment selection — but regulatory barriers are blocking access for the patients who need it most.
In Vivo - July 8, 2026
Early data from ex vivo drug sensitivity platforms suggest functional precision medicine could transform cancer treatment selection — but regulatory barriers are blocking access for the patients who need it most.
In Vivo - July 8, 2026
AstraZeneca Gains SBP’s PDE3/4 Inhibitor To Bolster COPD Inhalant Portfolio
Deal Snapshot: AstraZeneca is paying Sino Biopharmaceutical up to $1.9bn to license ex-China rights to TQC3721, a PDE3/PDE4 inhibitor, in a move set to bolster the UK major’s established status in inhalant therapies for COPD.
Scrip - July 8, 2026
Deal Snapshot: AstraZeneca is paying Sino Biopharmaceutical up to $1.9bn to license ex-China rights to TQC3721, a PDE3/PDE4 inhibitor, in a move set to bolster the UK major’s established status in inhalant therapies for COPD.
Scrip - July 8, 2026
Prazer Targets The Undruggable With Dual-Pathway TPD Platform
Prazer CEO talks to Scrip about how the Korean biotech is advancing its proprietary TPD platform, designed to target both proteasome and lysosomal degradation pathways, to address targets inaccessible to conventional approaches.
Scrip - July 8, 2026
Prazer CEO talks to Scrip about how the Korean biotech is advancing its proprietary TPD platform, designed to target both proteasome and lysosomal degradation pathways, to address targets inaccessible to conventional approaches.
Scrip - July 8, 2026
Q&A With Unilever Senior VP On US Innovation Center
HBW Insight chats with Leo Aquino, SVP R&D, Unilever North America, on the significance of the company's new innovation center in New Haven, Conn.
HBW Insight - July 8, 2026
HBW Insight chats with Leo Aquino, SVP R&D, Unilever North America, on the significance of the company's new innovation center in New Haven, Conn.
HBW Insight - July 8, 2026
Insilico’s Bold Move To Take AI-Discovered Asset Into Phase III
Unable to find a partner to share the risk on its novel idiopathic pulmonary fibrosis asset, Insilico is moving into late-stage testing on its own.
Scrip - July 8, 2026
Unable to find a partner to share the risk on its novel idiopathic pulmonary fibrosis asset, Insilico is moving into late-stage testing on its own.
Scrip - July 8, 2026
Vera Edges Vertex In IgAN Race As FDA Approves Trutakna
Trutakna becomes the first BAFF/APRIL inhibitor approved for IgAN, a new approach in a market already crowded with several therapies.
Scrip - July 8, 2026
Trutakna becomes the first BAFF/APRIL inhibitor approved for IgAN, a new approach in a market already crowded with several therapies.
Scrip - July 8, 2026
AstraZeneca Gains SBP’s PDE3/4 Inhibitor To Bolster COPD Inhalant Portfolio
Deal Snapshot: AstraZeneca is paying Sino Biopharmaceutical up to $1.9bn to license ex-China rights to TQC3721, a PDE3/PDE4 inhibitor, in a move set to bolster the UK major’s established status in inhalant therapies for COPD.
Scrip - July 8, 2026
Deal Snapshot: AstraZeneca is paying Sino Biopharmaceutical up to $1.9bn to license ex-China rights to TQC3721, a PDE3/PDE4 inhibitor, in a move set to bolster the UK major’s established status in inhalant therapies for COPD.
Scrip - July 8, 2026
Prazer Targets The Undruggable With Dual-Pathway TPD Platform
Prazer CEO talks to Scrip about how the Korean biotech is advancing its proprietary TPD platform, designed to target both proteasome and lysosomal degradation pathways, to address targets inaccessible to conventional approaches.
Scrip - July 8, 2026
Prazer CEO talks to Scrip about how the Korean biotech is advancing its proprietary TPD platform, designed to target both proteasome and lysosomal degradation pathways, to address targets inaccessible to conventional approaches.
Scrip - July 8, 2026
ResMed Sells MatrixCare Software Business For $490m In Portfolio Overhaul
The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy.
Medtech Insight - July 8, 2026
The eight-year post-acute care software venture is sold to Frazier Healthcare Partners at a notable discount from its 2018 acquisition price as the medtech leader pivots toward its 2030 growth strategy.
Medtech Insight - July 8, 2026
Physicians Reviewing ChatGPT Responses To Improve Healthcare Answers
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
HBW Insight - July 8, 2026
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
HBW Insight - July 8, 2026
Q&A With Unilever Senior VP On US Innovation Center
HBW Insight chats with Leo Aquino, SVP R&D, Unilever North America, on the significance of the company's new innovation center in New Haven, Conn.
HBW Insight - July 8, 2026
HBW Insight chats with Leo Aquino, SVP R&D, Unilever North America, on the significance of the company's new innovation center in New Haven, Conn.
HBW Insight - July 8, 2026
Amneal Gets Selected For US FDA’s Domestic Manufacturing Pilot
Amneal's new Brookhaven sterile plant joins six other facilities in the FDA's PreCheck pilot, which fast-tracks regulatory engagement for domestic manufacturers.
Generics Bulletin - July 8, 2026
Amneal's new Brookhaven sterile plant joins six other facilities in the FDA's PreCheck pilot, which fast-tracks regulatory engagement for domestic manufacturers.
Generics Bulletin - July 8, 2026
‘Crises And Challenges’ – How An Embattled European Off-Patent Industry Is Fighting Global Pressures
With Europe’s off-patent industry struggling to deal with pressures including the Urban Waste Water Treatment Directive, the impact of the US MFN policy and competition from China, Medicines for Europe’s leaders talk about how the generics and biosimilars sector is pushing back.
Generics Bulletin - July 8, 2026
With Europe’s off-patent industry struggling to deal with pressures including the Urban Waste Water Treatment Directive, the impact of the US MFN policy and competition from China, Medicines for Europe’s leaders talk about how the generics and biosimilars sector is pushing back.
Generics Bulletin - July 8, 2026
Split Federal Circuit Keeps Hetero’s Nuedexta Generic Sidelined
Otsuka has fended off Hetero Labs’ US generic version of its Nuedexta at the Federal Circuit, which upheld a preliminary injunction blocking the generic – but only until the underlying patent expires in August, and on condition that Otsuka now posts a bond.
Generics Bulletin - July 8, 2026
Otsuka has fended off Hetero Labs’ US generic version of its Nuedexta at the Federal Circuit, which upheld a preliminary injunction blocking the generic – but only until the underlying patent expires in August, and on condition that Otsuka now posts a bond.
Generics Bulletin - July 8, 2026
Deals Shaping The Industry, June 2026
An interactive look at pharma, medtech and diagnostics deals made during June 2026. Data courtesy of Biomedtracker.
In Vivo - July 8, 2026
An interactive look at pharma, medtech and diagnostics deals made during June 2026. Data courtesy of Biomedtracker.
In Vivo - July 8, 2026
The Race To Commercialize Functional Precision Medicine And The Policy Battle Shaping It
Early data from ex vivo drug sensitivity platforms suggest functional precision medicine could transform cancer treatment selection — but regulatory barriers are blocking access for the patients who need it most.
In Vivo - July 8, 2026
Early data from ex vivo drug sensitivity platforms suggest functional precision medicine could transform cancer treatment selection — but regulatory barriers are blocking access for the patients who need it most.
In Vivo - July 8, 2026